325 related articles for article (PubMed ID: 27399335)
1. FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation.
Tong J; Tan S; Zou F; Yu J; Zhang L
Oncogene; 2017 Feb; 36(6):787-796. PubMed ID: 27399335
[TBL] [Abstract][Full Text] [Related]
2. Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer.
Song X; Shen L; Tong J; Kuang C; Zeng S; Schoen RE; Yu J; Pei H; Zhang L
Theranostics; 2020; 10(18):8098-8110. PubMed ID: 32724460
[TBL] [Abstract][Full Text] [Related]
3. Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non-Small Cell Lung Cancer.
Ye M; Zhang Y; Zhang X; Zhang J; Jing P; Cao L; Li N; Li X; Yao L; Zhang J; Zhang J
Cancer Res; 2017 Jul; 77(13):3527-3539. PubMed ID: 28522751
[TBL] [Abstract][Full Text] [Related]
4. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction.
Inuzuka H; Shaik S; Onoyama I; Gao D; Tseng A; Maser RS; Zhai B; Wan L; Gutierrez A; Lau AW; Xiao Y; Christie AL; Aster J; Settleman J; Gygi SP; Kung AL; Look T; Nakayama KI; DePinho RA; Wei W
Nature; 2011 Mar; 471(7336):104-9. PubMed ID: 21368833
[TBL] [Abstract][Full Text] [Related]
5. The two faces of FBW7 in cancer drug resistance.
Wang Z; Fukushima H; Gao D; Inuzuka H; Wan L; Lau AW; Liu P; Wei W
Bioessays; 2011 Nov; 33(11):851-9. PubMed ID: 22006825
[TBL] [Abstract][Full Text] [Related]
6.
Tong J; Tan S; Nikolovska-Coleska Z; Yu J; Zou F; Zhang L
Mol Cancer Ther; 2017 Sep; 16(9):1979-1988. PubMed ID: 28619760
[TBL] [Abstract][Full Text] [Related]
7. Mcl-1 ubiquitination and destruction.
Inuzuka H; Fukushima H; Shaik S; Liu P; Lau AW; Wei W
Oncotarget; 2011 Mar; 2(3):239-44. PubMed ID: 21608150
[TBL] [Abstract][Full Text] [Related]
8. Fbw7 and p53 cooperatively suppress advanced and chromosomally unstable intestinal cancer.
Grim JE; Knoblaugh SE; Guthrie KA; Hagar A; Swanger J; Hespelt J; Delrow JJ; Small T; Grady WM; Nakayama KI; Clurman BE
Mol Cell Biol; 2012 Jun; 32(11):2160-7. PubMed ID: 22473991
[TBL] [Abstract][Full Text] [Related]
9. Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.
He L; Torres-Lockhart K; Forster N; Ramakrishnan S; Greninger P; Garnett MJ; McDermott U; Rothenberg SM; Benes CH; Ellisen LW
Cancer Discov; 2013 Mar; 3(3):324-37. PubMed ID: 23274910
[TBL] [Abstract][Full Text] [Related]
10. Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradicate Colon Cancer Cells.
Tong J; Wang P; Tan S; Chen D; Nikolovska-Coleska Z; Zou F; Yu J; Zhang L
Cancer Res; 2017 May; 77(9):2512-2521. PubMed ID: 28202514
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7.
Wertz IE; Kusam S; Lam C; Okamoto T; Sandoval W; Anderson DJ; Helgason E; Ernst JA; Eby M; Liu J; Belmont LD; Kaminker JS; O'Rourke KM; Pujara K; Kohli PB; Johnson AR; Chiu ML; Lill JR; Jackson PK; Fairbrother WJ; Seshagiri S; Ludlam MJ; Leong KG; Dueber EC; Maecker H; Huang DC; Dixit VM
Nature; 2011 Mar; 471(7336):110-4. PubMed ID: 21368834
[TBL] [Abstract][Full Text] [Related]
12. ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer.
Ji S; Qin Y; Shi S; Liu X; Hu H; Zhou H; Gao J; Zhang B; Xu W; Liu J; Liang D; Liu L; Liu C; Long J; Zhou H; Chiao PJ; Xu J; Ni Q; Gao D; Yu X
Cell Res; 2015 May; 25(5):561-73. PubMed ID: 25753158
[TBL] [Abstract][Full Text] [Related]
13. F-box and WD repeat domain-containing 7 regulates intestinal cell lineage commitment and is a haploinsufficient tumor suppressor.
Sancho R; Jandke A; Davis H; Diefenbacher ME; Tomlinson I; Behrens A
Gastroenterology; 2010 Sep; 139(3):929-41. PubMed ID: 20638938
[TBL] [Abstract][Full Text] [Related]
14. Regulation of GATA-binding protein 2 levels via ubiquitin-dependent degradation by Fbw7: involvement of cyclin B-cyclin-dependent kinase 1-mediated phosphorylation of THR176 in GATA-binding protein 2.
Nakajima T; Kitagawa K; Ohhata T; Sakai S; Uchida C; Shibata K; Minegishi N; Yumimoto K; Nakayama KI; Masumoto K; Katou F; Niida H; Kitagawa M
J Biol Chem; 2015 Apr; 290(16):10368-81. PubMed ID: 25670854
[TBL] [Abstract][Full Text] [Related]
15. Global and context-specific transcriptional consequences of oncogenic Fbw7 mutations.
Thirimanne HN; Wu F; Janssens DH; Swanger J; Diab A; Feldman HM; Amezquita RA; Gottardo R; Paddison PJ; Henikoff S; Clurman BE
Elife; 2022 Feb; 11():. PubMed ID: 35225231
[TBL] [Abstract][Full Text] [Related]
16. Aberrant regulation of FBW7 in cancer.
Wang L; Ye X; Liu Y; Wei W; Wang Z
Oncotarget; 2014 Apr; 5(8):2000-15. PubMed ID: 24899581
[TBL] [Abstract][Full Text] [Related]
17. Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.
Fan LC; Teng HW; Shiau CW; Tai WT; Hung MH; Yang SH; Jiang JK; Chen KF
Oncotarget; 2016 Sep; 7(39):64136-64147. PubMed ID: 27580057
[TBL] [Abstract][Full Text] [Related]
18. FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma.
Suryo Rahmanto A; Savov V; Brunner A; Bolin S; Weishaupt H; Malyukova A; Rosén G; Čančer M; Hutter S; Sundström A; Kawauchi D; Jones DT; Spruck C; Taylor MD; Cho YJ; Pfister SM; Kool M; Korshunov A; Swartling FJ; Sangfelt O
EMBO J; 2016 Oct; 35(20):2192-2212. PubMed ID: 27625374
[TBL] [Abstract][Full Text] [Related]
19. Trametinib potentiates TRAIL-induced apoptosis via FBW7-dependent Mcl-1 degradation in colorectal cancer cells.
Lin L; Ding D; Xiao X; Li B; Cao P; Li S
J Cell Mol Med; 2020 Jun; 24(12):6822-6832. PubMed ID: 32352219
[TBL] [Abstract][Full Text] [Related]
20. Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase.
Min SH; Lau AW; Lee TH; Inuzuka H; Wei S; Huang P; Shaik S; Lee DY; Finn G; Balastik M; Chen CH; Luo M; Tron AE; Decaprio JA; Zhou XZ; Wei W; Lu KP
Mol Cell; 2012 Jun; 46(6):771-83. PubMed ID: 22608923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
